Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Date:7/14/2008

>

Notes payable, less current portion - 119,000

Capital lease obligation, less current portion 22,000 30,000

Deferred license revenue - 4,000

Commitments and contingencies

STOCKHOLDERS' EQUITY:

Preferred stock - $.001 par value; authorized

5,000,000 shares; non-voting; nil shares

outstanding - -

Common stock - $.001 par value; authorized

325,000,000 shares; outstanding - 226,210,617

and 196,112,201, respectively 226,000 196,000

Additional paid-in-capital 246,205,000 224,453,000

Accumulated deficit (230,836,000) (207,660,000)

Total stockholders' equity 15,595,000 16,989,000

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $23,057,000 $22,997,000

-continued-

PEREGRINE PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2008

2008 2007 2006

REVENUES:

Contract manufacturing

revenue $5,897,000 $3,492,000 $3,005,000

License revenue 196,000 216,000 188,000

Total revenues 6,093,000 3,708,000 3,193,000

COSTS AND EXPENSES:

Cost of contract

manufacturing 4,804,000 3,296,000 3,297,000

Research and development 18,279,000 15,876,000 12,415,000

Selling, general and

administrative 7,150,000 6,446,000 6,564,000

Total costs and

expenses 30,233,000 25,618,000 22,276,000

LOSS FROM OPERATIONS (24,140,000) (21,910,000) (19,08
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
2. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
3. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
7. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015 VG Life Sciences, Inc., ... autoimmune and infectious diseases, announced that the U.S. ... important new composition of matter patent covering methods ... of CLIP. U.S. Patent No. ... Life Sciences, VG1177, a synthetic peptide which has ...
(Date:2/28/2015)... Increasing its efforts to resolve the GMO ... episodes of The GMO TRUTH podcast on both ITunes and ... continues its mission to discover the truth and change the ... “uncover the truth about the GMOs in our food supply,” ... Podcast is an expansion of the documentary/investigative film-making methodology in ...
(Date:2/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) ... of Trypsin" report to their offering. , ... providing comprehensive data on Trypsin globally and regionally ( ... North America , Latin America ... Trypsin This report focuses on three primary areas; ...
(Date:2/27/2015)... 27, 2015 FamilyFarms Group is pleased ... of State Line Farms, received the 2015 Tomorrow’s Top ... under the age of 35, who has demonstrated excellence ... honor to win the Tomorrow's Top Producer Horizon Award. ... the Top Producer Award and learning from their experiences. ...
Breaking Biology Technology:VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Global Market Report of Trypsin 2014-2018 2Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
... for prognostication and this one is no different. Like a ... has been laboring up, up, up the steep incline of recovery. ... of payback, a little joy ride. And to be clear in ... not the white-knuckled death plummet we have not yet forgotten. , ...
... the ever-expanding realm of content management systems (CMS) providers, ... things simple for clients. Forget the gearhead techno-speak. The ... and business issues through plain talk and better Web ... use the Web, said Pat Bieser, founder and CEO ...
... the University of Wisconsin-Madison received their grades online for the ... and implemented by a team of staff members from the ... Office of the Registrar . , ,We worked ... of what we would release to instructors, said Connie Chatman, ...
Cached Biology Technology:Year ahead offers payoff for hard work 2Year ahead offers payoff for hard work 3Untangling the Web: Northwoods Software in profile 2Untangling the Web: Northwoods Software in profile 3Untangling the Web: Northwoods Software in profile 4Untangling the Web: Northwoods Software in profile 5UW-Madisons move to online grading goes smoothly 2
(Date:2/12/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announced today ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE SERVICES ... NXT-ID,s position in the emerging "Internet of Things" by ... multiple devices to collaborate with one another to improve ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Conference on January 29 th at 10:30 a.m. ... of NXT-ID will present and host a live Q&A ... and its full suite of biometric technologies. Investors can ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... of all animal species in the world are insects. ... Beetles can be very beautiful and colorful, but many ... destroy food plants like potatoes (the Colorado potato beetle) ... cause U.S. $ 26 billion in losses to U.S. ...
... 25, 2008) The American Physiological Society (APS; ... 2008 Minority Outreach Fellowships to TanYa Gwathmey and Kesia ... program. Dr. Gwathmey, an African-American, is a postdoctoral ... the Wake Forest University School of Medicine in Winston-Salem, ...
... 25, 2008 -- Scientists at Harvard University have ... animals called bdelloid rotifers are extraordinarily resistant to ... doses of gamma radiation much greater than that ... date. Because free radicals such as those ...
Cached Biology News:APS names 2 minority outreach fellows 2APS names 2 minority outreach fellows 3Common aquatic animals show extreme resistance to radiation 2
See product name for description....
... Custom Production Service - Conjugation ... Conjugation Biotin Conjugation Fluorescein Isothiocyanate ... Conjugation Allophycocyanin Conjugation Alexa Fluor ... Alexa Fluor 405 Conjugation Rpe-Alexa ...
... Design , Customer Peptide Synthesis , 20 Amino Acid ... , 20 mg will return to customer for future usage ... 2 , Maintenance 102 days/each , ... x5 /each , Test bleed (app. 5 ...
Request Info...
Biology Products: